WO1997000319A3 - Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante - Google Patents
Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante Download PDFInfo
- Publication number
- WO1997000319A3 WO1997000319A3 PCT/GB1996/001388 GB9601388W WO9700319A3 WO 1997000319 A3 WO1997000319 A3 WO 1997000319A3 GB 9601388 W GB9601388 W GB 9601388W WO 9700319 A3 WO9700319 A3 WO 9700319A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leptin
- domain
- chimeric
- immunoglobulin domain
- fused
- Prior art date
Links
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract 5
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000016267 Leptin Human genes 0.000 title abstract 3
- 108010092277 Leptin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 229940039781 leptin Drugs 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60110/96A AU6011096A (en) | 1995-06-13 | 1996-06-11 | Chimeric leptin fused to immunoglobulin domain and use |
EP96917584A EP0832219A2 (fr) | 1995-06-13 | 1996-06-11 | Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante |
JP9502784A JPH11507547A (ja) | 1995-06-13 | 1996-06-11 | 免疫グロブリンドメインと融合したキメラレプチンおよびその用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9511935.0A GB9511935D0 (en) | 1995-06-13 | 1995-06-13 | Novel compound |
GB9511935.0 | 1995-06-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08981783 A-371-Of-International | 1998-09-18 | ||
US09/859,361 Continuation US20020058311A1 (en) | 1995-06-13 | 2001-05-17 | Chimeric leptin fused to immunoglobulin domain and use |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997000319A2 WO1997000319A2 (fr) | 1997-01-03 |
WO1997000319A3 true WO1997000319A3 (fr) | 1997-04-10 |
Family
ID=10775951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/001388 WO1997000319A2 (fr) | 1995-06-13 | 1996-06-11 | Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0832219A2 (fr) |
JP (1) | JPH11507547A (fr) |
AU (1) | AU6011096A (fr) |
CA (1) | CA2224646A1 (fr) |
GB (1) | GB9511935D0 (fr) |
WO (1) | WO1997000319A2 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6838260B2 (en) | 1997-12-08 | 2005-01-04 | Emd Lexigen Research Center Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US6969517B2 (en) | 2001-05-03 | 2005-11-29 | Emd Lexigen Research Center Corp. | Recombinant tumor specific antibody and use thereof |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7141651B2 (en) | 1999-08-09 | 2006-11-28 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
US7148321B2 (en) | 2001-03-07 | 2006-12-12 | Emd Lexigen Research Center Corp. | Expression technology for proteins containing a hybrid isotype antibody moiety |
US7169904B2 (en) | 2002-12-17 | 2007-01-30 | Emd Lexigen Research Center Corp. | Immunocytokine sequences and uses thereof |
US7186804B2 (en) | 2001-12-04 | 2007-03-06 | Emd Lexigen Research Center Corp. | IL-2 fusion proteins with modulated selectivity |
US7211253B1 (en) | 1999-11-12 | 2007-05-01 | Merck Patentgesellschaft Mit Beschrankter Haftung | Erythropoietin forms with improved properties |
US7323549B2 (en) | 2003-12-30 | 2008-01-29 | Emd Lexigen Research Center Corp. | IL-7 fusion proteins |
US7465447B2 (en) | 2003-12-31 | 2008-12-16 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
US7507406B2 (en) | 2000-02-11 | 2009-03-24 | Emd Serono Research Center, Inc. | Enhancing the circulating half-life of antibody-based fusion proteins |
US7517526B2 (en) | 2000-06-29 | 2009-04-14 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
US7589179B2 (en) | 2004-12-09 | 2009-09-15 | Merck Patent Gmbh | IL-7 variants with reduced immunogenicity |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6310034B1 (en) | 1993-05-21 | 2001-10-30 | Ut-Battelle, Llc | Agouti polypeptide compositions |
US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
IL124442A0 (en) * | 1995-11-22 | 1998-12-06 | Amgen Inc | Methods of increasing lean tissue mass using ob protein compositions |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
AU769250B2 (en) * | 1995-12-27 | 2004-01-22 | Genentech Inc. | OB protein derivatives having prolonged half-life |
CN1154726C (zh) * | 1995-12-27 | 2004-06-23 | 基因技术股份有限公司 | 具长半衰期的ob蛋白质衍生物 |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
AU770897B2 (en) * | 1996-12-20 | 2004-03-04 | Amgen, Inc. | OB fusion protein compositions and methods |
JP4175668B2 (ja) * | 1996-12-20 | 2008-11-05 | アムジエン・インコーポレーテツド | Ob融合タンパク質組成物および方法 |
JP2001512483A (ja) * | 1997-02-25 | 2001-08-21 | イーライ リリー アンド カンパニー | レプチンレセプターリガンドによる不妊症の治療 |
AU2002300605B8 (en) * | 1997-04-17 | 2006-02-09 | Amgen Inc. | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods |
IL132380A0 (en) * | 1997-04-17 | 2001-03-19 | Amgen Inc | Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods |
US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
US6187564B1 (en) | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
AU8182298A (en) * | 1997-07-10 | 1999-02-08 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
AU758240B2 (en) * | 1998-02-25 | 2003-03-20 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
WO2000007014A2 (fr) | 1998-07-28 | 2000-02-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Induction de genes a mediation par la leptine |
MXPA01006922A (es) * | 1999-01-07 | 2002-04-24 | Lexigen Pharm Corp | Expresion y exportacion de proteinas de anti-obesidad como proteinas de fusion en fc. |
WO2000068376A1 (fr) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Nouveaux polypeptides d'erythropoietine du chimpanze (chepo) et acides nucleiques codant pour ces memes polypeptides |
WO2001025428A1 (fr) * | 1999-10-01 | 2001-04-12 | Eli Lilly And Company | Nouvel homologue humain de la leptine |
JP4756813B2 (ja) | 2000-05-22 | 2011-08-24 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | レセプターを用いた相互作用の捕捉法 |
US7235629B2 (en) | 2000-11-14 | 2007-06-26 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Functional fragment of the leptin receptor |
US7189830B2 (en) * | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
DE602004011770T2 (de) * | 2003-06-12 | 2009-02-05 | Eli Lilly And Co., Indianapolis | Fusionsproteine |
PT1641823E (pt) | 2003-06-12 | 2011-11-08 | Lilly Co Eli | Proteínas de fusão de análogos de glp-1 |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
DK2239273T3 (da) | 2003-11-13 | 2013-12-09 | Hanmi Science Co Ltd | Farmaceutisk sammensætning, der omfatter en immunoglobulin Fc-region som en bærer |
CA2552590A1 (fr) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Composes de ciblage |
US7423113B2 (en) | 2004-08-25 | 2008-09-09 | Vib Vzw | Leptin antagonist |
CA2585549A1 (fr) | 2004-11-18 | 2006-05-26 | Vib Vzw | Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine |
JP2008525452A (ja) * | 2004-12-22 | 2008-07-17 | イーライ リリー アンド カンパニー | Glp−1類似体融合蛋白質製剤 |
AU2007209201A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
EP2421896A1 (fr) | 2009-04-22 | 2012-02-29 | Merck Patent GmbH | Protéines de fusion à des anticorps avec des sites de liaison à fcrn modifiés |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464533A1 (fr) * | 1990-06-28 | 1992-01-08 | BEHRINGWERKE Aktiengesellschaft | Protéines fusionnées avec des portions d'immunoglobulines, leurs production et utilisation |
WO1996005309A2 (fr) * | 1994-08-17 | 1996-02-22 | The Rockefeller University | Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques |
WO1996034885A2 (fr) * | 1995-05-05 | 1996-11-07 | Smithkline Beecham Plc | Fragments peptidiques biologiquement actifs de proteines ob |
WO1996035787A1 (fr) * | 1995-05-08 | 1996-11-14 | Chiron Corporation | Acides nucleiques pour traiter l'obesite |
-
1995
- 1995-06-13 GB GBGB9511935.0A patent/GB9511935D0/en active Pending
-
1996
- 1996-06-11 WO PCT/GB1996/001388 patent/WO1997000319A2/fr not_active Application Discontinuation
- 1996-06-11 EP EP96917584A patent/EP0832219A2/fr not_active Withdrawn
- 1996-06-11 CA CA002224646A patent/CA2224646A1/fr not_active Abandoned
- 1996-06-11 JP JP9502784A patent/JPH11507547A/ja active Pending
- 1996-06-11 AU AU60110/96A patent/AU6011096A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464533A1 (fr) * | 1990-06-28 | 1992-01-08 | BEHRINGWERKE Aktiengesellschaft | Protéines fusionnées avec des portions d'immunoglobulines, leurs production et utilisation |
WO1996005309A2 (fr) * | 1994-08-17 | 1996-02-22 | The Rockefeller University | Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques |
WO1996034885A2 (fr) * | 1995-05-05 | 1996-11-07 | Smithkline Beecham Plc | Fragments peptidiques biologiquement actifs de proteines ob |
WO1996035787A1 (fr) * | 1995-05-08 | 1996-11-14 | Chiron Corporation | Acides nucleiques pour traiter l'obesite |
Non-Patent Citations (1)
Title |
---|
YIYING ZHANG ET AL: "POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOGUE", NATURE, vol. 372, no. 6505, 1 December 1994 (1994-12-01), pages 425 - 432, XP000602062 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226998B2 (en) | 1997-12-08 | 2007-06-05 | Emd Lexigen Research Center Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US7576193B2 (en) | 1997-12-08 | 2009-08-18 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US6838260B2 (en) | 1997-12-08 | 2005-01-04 | Emd Lexigen Research Center Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7582288B2 (en) | 1999-08-09 | 2009-09-01 | Merck Patent Gmbh | Methods of targeting multiple cytokines |
US7141651B2 (en) | 1999-08-09 | 2006-11-28 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
US7211253B1 (en) | 1999-11-12 | 2007-05-01 | Merck Patentgesellschaft Mit Beschrankter Haftung | Erythropoietin forms with improved properties |
US7507406B2 (en) | 2000-02-11 | 2009-03-24 | Emd Serono Research Center, Inc. | Enhancing the circulating half-life of antibody-based fusion proteins |
US7517526B2 (en) | 2000-06-29 | 2009-04-14 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
US7148321B2 (en) | 2001-03-07 | 2006-12-12 | Emd Lexigen Research Center Corp. | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
US7601814B2 (en) | 2001-03-30 | 2009-10-13 | Merck Patent Gmbh | Reducing the immunogenicity of fusion proteins |
US7459538B2 (en) | 2001-05-03 | 2008-12-02 | Merck Patent Gmbh | Recombinant tumor specific antibody and use thereof |
US6969517B2 (en) | 2001-05-03 | 2005-11-29 | Emd Lexigen Research Center Corp. | Recombinant tumor specific antibody and use thereof |
US7462350B2 (en) | 2001-12-04 | 2008-12-09 | Emd Serono Research Center, Inc. | Cancer treatments including administering IL-2 fusion proteins with modulated selectivity |
US7186804B2 (en) | 2001-12-04 | 2007-03-06 | Emd Lexigen Research Center Corp. | IL-2 fusion proteins with modulated selectivity |
US7169904B2 (en) | 2002-12-17 | 2007-01-30 | Emd Lexigen Research Center Corp. | Immunocytokine sequences and uses thereof |
US7323549B2 (en) | 2003-12-30 | 2008-01-29 | Emd Lexigen Research Center Corp. | IL-7 fusion proteins |
US7465447B2 (en) | 2003-12-31 | 2008-12-16 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
US7589179B2 (en) | 2004-12-09 | 2009-09-15 | Merck Patent Gmbh | IL-7 variants with reduced immunogenicity |
Also Published As
Publication number | Publication date |
---|---|
JPH11507547A (ja) | 1999-07-06 |
WO1997000319A2 (fr) | 1997-01-03 |
GB9511935D0 (en) | 1995-08-09 |
AU6011096A (en) | 1997-01-15 |
CA2224646A1 (fr) | 1997-01-03 |
EP0832219A2 (fr) | 1998-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997000319A3 (fr) | Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante | |
NO20063000L (no) | Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav. | |
AU5673596A (en) | Rapid, stable high-titre production of recombinant retroviru s | |
AU2551797A (en) | Improved tissue destruction in cryosurgery by use of thermal hysteresis proteins | |
WO1996017924A3 (fr) | Nouveaux polypeptides issus d'une structure dite 'en herisson' | |
AU4426296A (en) | G protein coupled receptor protein, production, and use thereof | |
AU5801296A (en) | Crosslinkable polypeptide compositions | |
AU3126600A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
AU6124196A (en) | Novel dolastatin derivatives, their preparation and use | |
AU5229498A (en) | Mutants of the lag-3 proteins, products for the expression of these mutants and use | |
AU4061597A (en) | Treatment of the common cold or allergic rhinitis | |
AU1952497A (en) | Novel antibody-cytokine fusion protein, and methods of making and using the same | |
AU4018897A (en) | Novel 3,4-diaryloxazolone derivatives, methods of preparation and therapeutic uses thereof | |
EP0875567A3 (fr) | Protéines à doigts de zinc se liant à l'oncogène mycm ainsi comment leur préparation et utilisation | |
AU4131296A (en) | Treatment of disorders with duloxetine | |
AU2467395A (en) | Novel ophthalmologic uses of protein c | |
AU1576999A (en) | Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation | |
AU4561497A (en) | Human rantes mutants incapable of aggregate formation | |
AU4075797A (en) | Outer membrane protein b1 of moraxella catarrhalis | |
AU6264596A (en) | Diagnosis, prognosis and monitoring of angiogenesis dependen t diseases | |
AU5395194A (en) | Process for the manufacture of 1,1,1,2-tetrafluoro-2- chloroethane and of pentafluoroethane | |
IL125002A0 (en) | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases | |
AU3241895A (en) | Apoptosis related protein bcl-y, and methods of use thereof | |
AU6928696A (en) | Free-flowing granules based on organic acids, preparation of said granules and their use | |
AU6714996A (en) | 2-(fluorenonyl)-carbapenems, compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2224646 Country of ref document: CA Ref country code: CA Ref document number: 2224646 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 1997 502784 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996917584 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996917584 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996917584 Country of ref document: EP |